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Vascular Endothelial Growth Factors
Biology and Current Status of Clinical Applications in Cardiovascular Medicine
Seppo Ylä-Herttuala, MD, PHD, FESC,*†§ Tuomas T. Rissanen, MD, PHD,* Ismo Vajanto, MD,‡
Juha Hartikainen, MD, PHD†
Kuopio, Finland
Members of the vascular endothelial growth factor (VEGF) family are among the most powerful modulators of
vascular biology. They regulate vasculogenesis, angiogenesis, and vascular maintenance during embryogenesis
and in adults. Because of their profound effects on blood vessels, VEGFs have received much attention regarding
their potential therapeutic use in cardiovascular medicine, especially for therapeutic vascular growth in myocar-
dial and peripheral ischemia. However, completed randomized controlled VEGF trials have not provided convinc-
ing evidence of clinical efficacy. On the other hand, recent preclinical proangiogenic VEGF studies have given
insight, and anti-VEGF studies have shown that the disturbance of vascular homeostasis by blocking VEGF-A may
lead to endothelial dysfunction and adverse vascular effects. Excess VEGF-A may contribute to neovasculariza-
tion of atherosclerotic lesions but, currently, there is no evidence that transient overexpression by gene transfer
could lead to plaque destabilization. Here, we review the biology and effects of VEGFs as well as the current sta-
tus of clinical applications and future perspectives of the therapeutic use of VEGFs in cardiovascular
medicine. (J Am Coll Cardiol 2007;49:1015–26) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.09.053t
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mherapeutic vascular growth is a new concept for the
reatment of ischemic vascular diseases. It involves stimula-
ion of angiogenesis, arteriogenesis, and lymphangiogenesis
1). Angiogenesis means sprouting, bridging, intussuscep-
ion, and/or enlargement of capillaries from the pre-existing
nes, whereas arteriogenesis is the in situ enlargement and
rowth of muscular collateral vessels from pre-existing
rteriolar anastomoses. Lymphangiogenesis, which will not
e covered in this review, means the generation of new
ymphatic vessels from the pre-existing ones. The members
f the vascular endothelial growth factor (VEGF) family
egulate all types of vascular growth. Various strategies also
ave been presented for the use of postnatal vasculogenesis,
.e., de novo differentiation and formation of vascular
tructures from endothelial progenitor cells and other stem
ells, which could be augmented with VEGFs. Thus far,
linical trials using VEGFs delivered as recombinant protein
r via gene transfer for the treatment of myocardial or
eripheral ischemia have not shown convincing efficacy. In
rom the *Department of Biotechnology and Molecular Medicine, A.I. Virtanen
nstitute, Kuopio University; †Department of Medicine and ‡Department of Surgery,
uopio University and Kuopio University Hospital; and §Gene Therapy Unit,
uopio University Hospital, Kuopio, Finland. This study was supported by grants
rom the Academy of Finland, Finnish Foundation of Cardiovascular Research, Sigrid
uselius Foundation, Kuopio University Hospital (EVO grant 5223), European
ascular Genomics Network, EVGN (LSHM-CT-2003-503254), and EU Clini-
ene network (LSH-CT-2004-018933). Drs. Ylä-Herttuala and Rissanen contrib-
ted equally to this work.s
Manuscript received April 17, 2006; revised manuscript received September 22,
006, accepted September 27, 2006.his review, we summarize the biology of VEGFs, preclin-
cal and clinical advances, and discuss why VEGF therapy
as not yet fulfilled the expectations. In addition to cardio-
ascular biology, VEGFs also play very important roles in
umor angiogenesis, retinal neovascularization, age-related
acular degeneration, rheumatoid arthritis, and psoriasis,
nd the reader is referred to recent reviews covering these
reas of VEGF biology (2,3).
he Biology of VEGF Family
he first member and the master regulator of angiogenesis and
ascular permeability, VEGF-A (also called VEGF), was
loned in 1989 based on the pioneering studies of an unknown
ngiogenesis and vascular permeability factor in the 1970s and
980s (4–6). After the discovery of VEGF-A, 4 other mem-
ers in the human VEGF family have been identified:
EGF-B, VEGF-C (also called VEGF-2), VEGF-D, and
lacental growth factor (PlGF) (7–10). In addition to these
EGFs, viral VEGF homologs (collectively called VEGF-E)
nd snake venom VEGFs (called VEGF-F) have been found
11,12). The properties of different VEGF family members are
hown in Table 1. The downstream signals of VEGFs in the
ascular endothelium are mediated by 3 tyrosine kinase-
ignaling receptors (VEGF receptor [VEGFR]-1, -2, and -3)
s shown in Figure 1.
Hypoxia increases VEGF-A expression via up-regulation
f hypoxia-inducible factor-1, e.g., in acute human skeletal
uscle ischemia (13,14). Many growth factors and cytokines,uch as platelet-derived growth factor-BB, PlGF, transform-
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VEGFs in Cardiovascular Medicine March 13, 2007:1015–26ing growth factor-, insulin-like
growth factor-1, fibroblast growth
factors, hepatocyte growth fac-
tor, tumor necrosis factor-, and
interleukin-1 up-regulate VEGF-A
expression (2,15). VEGF-A is
one of the strongest known in-
ducers of vascular permeability,
which occurs only within min-
utes after exposure to VEGF-A,
probably as the result of efficient
simultaneous nitric oxide (NO)
and prostacyclin production (16,17).
Because of its major role in vas-
cular biology and because of its
high angiogenic potency, VEGF-A
has been the prime candidate for
therapeutic applications in vivo (1).
The role of PlGF and VEGF-B
in vascular biology has remained
elusive. PlGF and VEGF-B are
nly weak mitogens for endothelial cells (ECs) in vitro, and
hey do not significantly induce acute vascular permeability
8,16). In vivo, long-lasting exposure to PlGF or VEGF-B
romotes angiogenesis, vascular permeability, and may po-
entiate VEGF-induced vascular growth, likely via indirect
echanisms that are still poorly understood (18–21). The
EGF-C and -D form another VEGF subfamily. They
oth bind to VEGFR-2 and -3, and they are synthesized as
arge precursor forms that are proteolytically processed, e.g.,
y plasmin into mature forms (indicated by NC) com-
rising the central VEGF homology domain with much
igher affinity toward VEGFR-2 (9,10). Thus, the long
orms are mainly lymphangiogenic, whereas the mature
hort forms also are angiogenic and promote vascular
ermeability via NO-mediated mechanisms (22). The viral
EGF homologs and snake-venom VEGFs are relatively
pecific VEGFR-2 ligands and thus have considerable
ngiogenic potency (11,12).
EGF in Blood Vessel
omeostasis and Atherosclerosis
oth VEGF-A and -C are required for embryonic devel-
pment of blood and lymphatic vasculature, respectively
23,24) whereas PlGF, VEGF-B, and VEGF-D appear
ispensable for vascular development (25,26). In adults,
EGF-A is expressed in virtually all vascularized tissues,
specially in fenestrated and sinusoidal blood vessels in
ndocrine and secretory organs as well as in large blood
essels, skeletal muscle, and myocardium, suggesting that
ow physiological VEGF-A levels are needed for the main-
enance of general vascular homeostasis (27). On the other
and, VEGF-A up-regulation is important in active phys-
ological angiogenesis processes, such as corpus luteum
Abbreviations
and Acronyms
CAD  coronary artery
disease
CCS  Canadian
Cardiovascular Society
CLI  critical limb
ischemia
EC  endothelial cell
NO  nitric oxide
PAD  peripheral arterial
disease
PlGF  placental growth
factor
pu  particle units
SMC  smooth muscle cell
VEGF  vascular
endothelial growth factor
VEGFR  VEGF receptorevelopment and exercise-induced angiogenesis in skeletal ouscle, as well as in tissue regeneration after injury and
schemia (2,13). The essential role of VEGF-A in vascular
omeostasis is highlighted by the consequences of systemic
EGF-A inhibition in vivo by soluble VEGFR-1, e.g., in
reeclampsia (28). Clinical trials using the anti–VEGF-A
ntibody bevacizumab (Avastin; Genentech Inc., South San
rancisco, California) for cancer treatment have indicated
hat up to 5% of the treated patients may have an increased
isk of thromboembolic complications, including unstable
ngina, myocardial infarction, stroke, and deep vein throm-
osis in addition to the more common side effects of
ypertension and proteinuria (29). Because of the continu-
usly increasing use of systemic anti-VEGF therapy for
ancer, studies addressing the risks of this novel treatment
ould be important, especially in patients with previous
ardiovascular morbidity or multiple risk factors.
The contribution of VEGF-A or other members of the
EGF family to atherogenesis has gained a lot of attention in
he recent years but has still remained unclear. The progressive
xpression of VEGF-A in activated ECs, macrophages and
ifferentiated smooth muscle cells (SMCs) in atherosclerotic
esions and in-stent restenosis presenting neovascularization
uggests that VEGF-A might have a role in atherogenesis and
laque instability via proinflammatory and angiogenic mecha-
isms (30–33). This hypothesis has been supported by exper-
ments using cholesterol-fed ApoE/ApoB100 double knock-
ut mice and cholesterol-fed rabbits (34,35). The roles of other
EGFs in atherogenesis have been less studied (33).
Recently, the contribution of VEGFs to atherogenesis
as been challenged. First, systemic adenoviral gene transfer
f VEGF-A, -B, -C, or -D, as well as recombinant
EGF-A administration, did not alter plaque area or
acrophage influx in LDLR/ApoB48 double knockout
ice (36). Second, periadventitial and intra-arterial gene
ransfer of VEGF-A, -C, and -D has inhibited neointimal
rowth in many animal studies (37–41). Third, there has
een no evidence of increased atherogenesis in clinical trials
sing VEGF-A protein or gene transfer (42–47). In fact,
EGF-A polymorphism causing higher VEGF-A expres-
ion recently was found to be associated with a lower risk of
oronary artery disease in an epidemiological study (48).
Taken together, it appears that the effects of VEGF-A
re strongly dependent on its local concentration (Fig. 2).
ow physiological amounts of VEGF-A seem to be re-
uired for blood vascular homeostasis, EC survival, and
roduction of NO and prostacyclin, resulting in vasodilata-
ion, antithrombosis, and suppression of SMC proliferation,
.e., are vasculoprotective as hypothesized previously (49).
uch higher concentrations are required for angiogenic and
asculogenic effects (Fig. 2). In ischemia and vascular injury,
EGF-A up-regulation restores sufficient perfusion and the
ntegrity of the endothelium. VEGF-A, or other members
n the family, do not appear to have a role in the initiation
f atherogenesis. The progressive increase in VEGF-A
xpression during atherogenesis is likely secondary to hyp-
xia and inflammation in growing lesions. However, at the
The Properties of Different VEGFs
Table 1 The Properties of Different VEGFs
Ligand Isoforms Receptor Solubility Source in Adults Biological Activities Phenotype of Knockout Mouse
VEGF (VEGF-A) VEGF-A121, VEGF-A165 VEGF-A189, VEGF-A206
(also VEGF-A138/145/162/165b have been
described)
VEGFR-1 and -R-2, VEGF165
binds to neuropilin-1
and -2, VEGF145
neuropilin-2
VEGF121 soluble, longer
forms bind to
heparan sulfates
with increasing
affinity
Almost all vascularized tissues,
especially fenestrated and
sinusoidal endothelium,
up-regulated by ischemia
(via HIF-1)
Vasculogenesis, angiogenesis,
vascular homeostasis,
vascular permeability and
recruitment of bone
marrow-derived cells
Loss of even single VEGF allele
leads to embryonic lethality
due to impaired
vasculogenesis and
angiogenesis
PlGF PlGF131 (PlGF-1), PlGF152 (PlGF-2),
PlGF203 (PlGF-3)
VEGFR-1, PlGF152 binds to
neuropilin-1 and -2
PlGF131 and PlGF203
soluble, PlGF152
binds to heparan
sultates
Placenta, thyroid, lung, and
goiter
Angiogenesis, monocyte
migration, recruitment of
bone marrow-derived cells,
up-regulation of VEGF-A
Almost-normal phenotype and
fertile with minor defects in
vascular growth in
pathological conditions
VEGF-B VEGF-B167 and VEGF-B186 VEGFR-1 and neuropilin-1 VEGF-B167 binds to
heparan sulfates,
VEGF186 soluble
Heart, skeletal muscle, and
vascular smooth muscle
cells
Angiogenesis, recruitment of
bone marrow-derived cells
Almost-normal phenotype with
minor possible defects:
reduced heart size,
prolonged PQ-time, impaired
recovery from ischemia
VEGF-C (VEGF-2) Unprocessed and proteolytically processed
(NC) forms
VEGFR-2, -R-3, and
neuropilin-2, processing
increases receptor
affinity
Soluble Neuroendocrine organs, lung,
heart, kidney, and vascular
smooth muscle cells
Development of lymphatics
and lymphangiogenesis,
angiogenesis
Lethal because of impaired
development of lymphatics
VEGF-D Unprocessed and proteolytically processed
(NC) forms
VEGFR-2 and VEGFR-3,
processing increases
receptor affinity
Soluble Neuroendocrine organs, lung,
heart, skeletal muscle,
intestine, and vascular
smooth muscle cells
Lymphangiogenesis and
angiogenesis
Normal
VEGF-E — VEGFR-2 and neuropilin-1 Soluble Virus-derived Angiogenesis —
VEGF-F — VEGFR-2 Binds to heparan
sulfates
Snake venom Angiogenesis and vascular
permeability
—
HIF  hypoxia-inducible factor; PlGF  placental growth factor; VEGF  vascular endothelial growth factor.
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VEGFs in Cardiovascular Medicine March 13, 2007:1015–26oment the possibility that a long-term high-level
EGF-A expression in advanced atherosclerotic lesions
ould contribute to plaque neovascularization and plaque vul-
erability cannot be excluded even though direct evidence of
his cascade is currently lacking. In contrast, transient systemic
roduction of VEGFs via adenoviral gene transfer or recom-
inant protein therapy seems not to be sufficient to promote
rogression of atherosclerosis in mice or humans.
nsights From Preclinical VEGF Studies
he efforts to use VEGFs in vascular medicine have been
ased on their vasculoprotective and angiogenic properties
49). Consistently, early and some more recent experimental
tudies showed that gene transfers of VEGF-A, -C, and -D
revent restenosis after arterial injury in several animal models
37–41). However, the lack of beneficial clinical effect of
Figure 1 Binding of VEGF Family Members to 3 High-Affinity Re
The roles of vascular endothelial growth factor receptor (VEGFR)-2 and -3 as principal
(VEGFs) are well established, but the biology of VEGFR-1 is still poorly understood. VE
and acts as a negative regulator of angiogenesis. However, VEGFR-1 activation by plac
mobilization of EPCs in vivo. VEGFR-1 also mediates monocyte chemotaxis. Neuropilin
heparan sulfates and neuropilin co-receptors modulate the biological activities of diffe
tively bind to VEGFR-2. DAG  diacylglycerol; eNOS  endothelial nitric oxide synthase
vated protein kinase; NO  nitric oxide; NRP  neuropilin; PGI2  prostacyclin; PKC EGF-A gene transfer on restenosis (45) suggests that the sost suitable target for gene or protein therapy with VEGFs
ight be the treatment of myocardial or peripheral ischemia.
In addition to the receptor binding profiles, it appears
hat 2 important variables define the angiogenic efficacy of
EGFs. First, the local growth factor concentration is the
ey determinant of the degree of vascular growth (50), also
emonstrated by a clear dose-response with the number of
pplied viral particles in gene therapy experiments
15,51,52). Second, the volume per injection and the num-
er of injections in addition to the matrix-binding proper-
ies of the growth factor determine the spread of the
ngiogenic effects (22,52). Intramuscular gene transfer route
ields manifold higher gene transfer efficiency and angio-
enesis in the target tissue with less ectopic gene expression
han intra-arterially injected adenovirus (15). Whereas in-
ramuscular injections are feasible in peripheral muscles, the
eart is obviously a more difficult target. Currently, the most
ors on Endothelium and Downstream Signaling Cascades
ors of blood and lymphatic vessel effects of vascular endothelial growth factors
appears to mediate ligand-specific actions. It also exists as a soluble decoy receptor
growth factor (PlGF) and VEGF-B stimulates vascular growth and may result in the
-2 are co-receptors for some VEGFs and amplify intracellular signals. Affinity to
GFs. VEGF-C and -D are proteolytically processed into mature forms that also effec-
 endothelial precursor cell; IP3  inositol trisphosphate; MAPK  mitogen-acti-
in kinase C; PLC  phospholipase gamma.cept
regulat
GFR-1
ental
-1 and
rent VE
; EPC
proteophisticated way of transducing the myocardium is the use
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March 13, 2007:1015–26 VEGFs in Cardiovascular Medicinef percutaneous catheter injection systems such as NOGA
Biosense Webster, Markham, Ontario, Canada), which
llows transmural gene transfer in the heart (52,53). Re-
ombinant VEGF protein or naked plasmid-mediated
Figure 2 The Biological Response of VEGF-A in Adults
Is Dependent on its Local Tissue Concentration
Lack of sufficient vascular endothelial growth factor (VEGF)-A results in endo-
thelial dysfunction via diminished nitric oxide and prostacyclin production. Phys-
iological levels maintain vascular homeostasis and protection while higher
levels induce physiological vascular growth with sprouting angiogenesis and
moderate capillary enlargement. Very high VEGF-A levels promote aberrant vas-
cular growth, i.e., the formation of blood lacunae and glomeruloid bodies as
well as significant tissue edema.
Figure 3 Adenoviral AdVEGF-A165 Gene Transfer Promotes Effic
(A and F) CD31 immunostainings of normal rabbit skeletal muscle transduced intram
earlier demonstrate abundant enlargement of preexisting capillaries after AdVEGF-A ge
enlargement with AdVEGF-A occurs through cell proliferation (black arrowheads). Scal
thighs shows that perfusion is increased up to 27-fold 6 days after AdVEGF-A gene tra
of the ultrasound data show the increase in blood flow in the whole vascular tree, incl
imaging (MRI) using a superparamagnetic contrast agent (Resovist), which causes inte
dashed lines) as the result of high contrast concentration, i.e., blood volume. (E and J
AdLacZ-treated muscles. Muscle edema is obvious after AdVEGF-A gene transfer both
free fluid in between muscles after AdVEGF-A gene transfer; white arrowheads  prof
has been modified from Rissanen et al. (55) with the permission of Lippincott WilliamEGF gene transfer are not likely efficient enough to induce
elevant biological effects and therefore viral vectors should
e preferred (44,47,52).
During extensive preclinical studies in large animal models
n pigs and rabbits (15,22,52,54,55), which better mimic
uman situation than experiments using mice and rats, we
ound that preexisting capillaries were dramatically enlarged via
O-dependent proliferation of ECs and SMCs only a few
ays after adenoviral (Ad)VEGF-A165 and AdVEGF-D
NC
ene transfer, resulting in supraphysiological muscle perfusion
Fig. 3). In the process of “capillary arterialization,” preexisting
apillaries enlarge, strengthen their wall by SMC hypertrophy
ue to increased blood flow (leading to the formation of
rteriole-like vessels that significantly reduce peripheral resis-
ance), and may even function as shunts (55). Similar obser-
ations also have been found to occur with VEGF-A overex-
ression by other groups (56,57). Furthermore, in the quail
horioallantoic membrane the vessel density increased maxi-
ally at lower VEGF-A concentrations, but that vessel diam-
ter increased maximally at higher VEGF concentrations (58).
lood lacunae may be formed by a very high dose of
dVEGF-A165 (55). Importantly, local blood flow also ap-
ears to modulate the vascular growth response by
dVEGF-A into one that best serves the muscle’s needs, e.g.,
eading to more sprouting angiogenesis in ischemic muscles
55). Secondary to the capillary enlargement, both normal
rteries and collateral arteries as well as veins undergo com-
Angiogenesis and an Acute Increase In Tissue Perfusion
rly with AdLacZ or adenoviral vascular endothelial growth factor (AdVEGF)-A at 6 days
nsfer. (Insets) CD31 (blue)  BrDU (brown) double stainings show that capillary
50  m. (B and G) Longitudinal contrast-enhanced ultrasound imaging of rabbit
n the target muscle (inside brackets). (C and H) 3-dimensional (3D) reconstructions
arge vessels. (D and I) Transversal mid-thigh T2*-weighted magnetic resonance
signal loss in the AdVEGF-A transduced semimembranosus muscle (outlined with
d volume MRI maps visualize the difference in blood volume between AdVEGF-A and
sound and MRI. P  proximal end of the semimembranosus muscle; asterisks 
emoral artery; arrows  superficial femoral artery. The figure, excluding the insets,
lkins.ient
uscula
ne tra
e bar 
nsfer i
uding l
nsive
) Bloo
in ultra
ound f
s & Wi
p
5
v
s
O
i
(
(
P
t
g
a
a
m
d
c
g
o
H
c
(
a
g
b
c
F
c
c
f
u
s
u
p
a
t
h
s
c
o
d
a
i
A
t
m
m
s
(
v
C
P
g
p
i
a
d
n
w
t
p
E
fi
c
o
V
p
r
a
s
p
t
I
4
w
r
n
i
R
i
p
a
m
l
s
r
t
o
V
D
c
o
p
r
A
f
t
a
N
w
t
n
C
a
w
c
d
1020 Ylä-Herttuala et al. JACC Vol. 49, No. 10, 2007
VEGFs in Cardiovascular Medicine March 13, 2007:1015–26ensatory growth as the result of high blood flow (15,22,54–
6). Bone marrow-derived cells do not incorporate in growing
essels induced by VEGF-A as previously proposed but may
upport angiogenesis via paracrine mechanisms (56,59,60).
ther VEGFs than VEGF-A and -DNC also have signif-
cant potential as vascular therapeutics due to their angiogenic
VEGFR-2) or lymphangiogenic (VEGFR-3) properties
1,11,24). Interestingly, VEGFR-1 ligands VEGF-B and
lGF are also angiogenic both in ischemic and nonischemic
issues (18–21).
The most important side effect of successful angiogenic
ene transfer with adenoviral VEGFR-2 ligands VEGF-A
nd -D have is transient tissue edema, which can cause
ccumulation of fluid in between skeletal muscle compart-
ents and in the pericardium (22,51,52,55,61). Edema is
ose-dependent, correlates with the mean capillary size,
oincides with the peak perfusion increase after adenoviral
ene transfer, and has not caused significant tissue damage
r release of myocardial markers in large animal models.
owever, excess edema especially in the heart and in the
alf can potentially be hazardous and should be avoided
62). A “cocktail” gene transfer of other growth factors, such
s Ang-1, platelet-derived growth factor, or fibroblast
rowth factors in combination with VEGFs, could be used
ut currently there is no convincing data on this approach in
linically relevant models and overexpression of PDGFs or
GFs may even generate unwanted tissue fibrosis. Strong
orticosteroids, such as dexamethasone, counteract in-
reased VEGFR-2-mediated vascular permeability but un-
ortunately also inhibit angiogenesis (P. Korpisalo et al.,
npublished data, 2007). One possibility would be the
imultaneous stimulation of lymphatic vessel growth by
sing VEGFR-3 ligands to remove extravasated plasma
roteins.
Recently, constructs expressing genomic VEGF-A with
n emphasis on the long isoforms or VEGF-inducing
ranscription factors have been reported to be effective in
indlimb ischemia models (63–65). However, because tis-
ue edema results from the combined effect of increased
apillary pressure, perfusion and compromised integrity
f capillary wall due to cell proliferation in addition to the
irect vascular permeability effects of VEGFs, a complete
voidance of this side effect may be difficult, if not
mpossible. Although the angiogenic boost provided by
dVEGFs may be sufficient, e.g., when used as an adjuvant
herapy with conventional revascularization procedures,
ore optimal vascular growth may be achieved with a more
oderate but long-lasting expression that may result in the
tabilization of growing vessels and diminished tissue edema
57,66). A sophisticated possibility would be the use of
ector constructs with regulated promoters.
linical VEGF Trials
eripheral arterial disease. Despite advances in by-pass
rafting and multimodal percutaneous interventions, ap- aroximately one fifth of patients with chronic critical limb
schemic (CLI) cannot be treated by any conventional
pproach because of the severity and extent of the disease or
ue to a poor general status. This leaves a significant
umber of patients with peripheral arterial disease (PAD)
ithout any effective treatment. Thus, local proangiogenic
herapy might offer a new treatment option for these
atients.
arly nonrandomized, uncontrolled trials. Patients in the
rst VEGF trials were not suitable for surgical or endovas-
ular revascularization or they had failed other treatment
ptions and were at high risk of amputation. The use of
EGF-A gene therapy initially was tested using naked
lasmid DNA delivery and was reported to result in the
esolution of rest pain, increased collateral vasculature, and
n increase in ankle brachial pressure index (67,68). The
afety and feasibility of intra-arterial gene delivery to human
eripheral arteries with adenovirus was also tested using
iters from 1  108 to 3  1010 plaque-forming units (42).
ntramuscular injections of AdVEGF-A121 with titers from
 108.5 to 4  1010 particle units (pu) were shown to be
ell tolerated and improved endothelial function and flow
eserve at 30 days (69). A small uncontrolled study using
aked VEGF-A165 plasmid DNA showed more than 80%
mprovement in rest pain (70).
andomized, controlled trials. Only a couple of random-
zed, placebo-controlled VEGF trials have been reported on
atients with intermittent claudication or CLI (Table 2). In
randomized controlled phase II trial (n  54) of catheter-
ediated VEGF-A165 gene delivery using plasmid-
iposomes or adenoviruses, AdVEGF-A–treated patients
howed improved vascularity on digital subtraction angiog-
aphy at 3 months, but there were no differences between
he treatment and placebo groups in terms of clinical
utcomes (43). The RAVE (Regional Angiogenesis With
ascular Endothelial Growth Factor in Peripheral Arterial
isease) trial was a phase II randomized, placebo-
ontrolled, double-blind study testing the safety and efficacy
f intramuscularly administered AdVEGF-A121 in 105
atients with PAD (46). The patients were randomized to
eceive a low (4  109 pu) or high (4  1010 pu) dose of
dVEGF-A121 or placebo. No significant differences were
ound between the groups in the change in peak walking
ime at 3 months or in secondary end points, which were
nkle brachial pressure index and quality of life measures.
o severe side effects were noted, although transient edema
as associated with intramuscular AdVEGF-A121 gene
ransfer. In a double-blind, placebo-controlled study of
aked plasmid VEGF in 54 adult diabetic patients with
LI, there was no difference in the primary end point of the
mputation rate at 100 days but significant improvements
ere achieved in secondary endpoints (ABI and clinical
ondition) (71). Currently, the phase II randomized,
ouble-blind, placebo-controlled WALK trial is ongoing
ddressing the efficacy of adenoviral hypoxia-inducible
Phase II/III Clinical Trials Addressing the Efficacy of Therapeutic Angiogenesis With VEGF Protein or Gene Therapy
Table 2 Phase II/III Clinical Trials Addressing the Efficacy of Therapeutic Angiogenesis With VEGF Protein or Gene Therapy
Trial Therapeutic Agent Administration
Control
Treatment
Target
Disease n Primary End Point Results* Reference
VIVA trial Recombinant VEGF-A165
protein
Intracoronary infusion followed by IV
infusions
Vehicle CAD 178 ETT at 2 months Negative 44
VEGF Peripheral
Vascular
Disease trial
AdVEGF-A165 or
plasmid/liposome
VEGF-A165
Intra-arterial injection at the angioplasty
site
Ringer’s lactate PAD 54 Increased vascularity
in angiography at
3 months
Positive 43
KAT trial AdVEGF-A165 or
plasmid/liposome
VEGF-A165
Intra-coronary injection at the
angioplasty site
Ringer’s lactate CAD 103 Improved myocardial
perfusion at
6 months
Positive (adenovirus
group only)
45
REVASC trial AdVEGF-A121 Intramyocardial injection via mini-
thoracotomy
Best medical
treatment
CAD 67 Time to 1-mm ST-
segment depression
on ETT at 26 weeks
Positive 80
RAVE trial AdVEGF-A121 Intramuscular injections Vehicle (no virus) PAD 105 Peak walking time at
12 weeks
Negative 46
Euroinject One
trial
Naked VEGF-A165
plasmid
Percutaneous intramyocardial injections Placebo plasmid CAD 74 Improved myocardial
perfusion at
3 months
Negative 47
Groningen trial Naked VEGF-A165
plasmid
Intramuscular injections Saline PAD 54 Decrease in
amputation rate
Negative (secondary
end points
positive)
71
GENASIS trial Naked VEGF-C plasmid Percutaneous intramyocardial injections Vehicle CAD 295 (404 planned) ETT at 3 months Negative at interim
analysis, stopped
Unpublished
NORTHERN trial AdVEGF-A121 Percutaneous intramyocardial injections Vehicle CAD 120 (planned) Change in myocardial
perfusion in stress/
rest at 12 weeks
Ongoing Unpublished
NOVA trial AdVEGF-A121 Percutaneous intramyocardial injections Vehicle CAD 129 (planned) ETT at 26 weeks Stopped Unpublished
*Efficacy measured as the study protocol-defined primary or secondary end point.
Ad  adenovirus; CAD  coronary artery disease; ETT  exercise tolerance testing; IV  intravenous; PAD  peripheral arterial disease; VEGF  vascular endothelial growth factor.
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ately 300 patients with PAD.
oronary artery disease (CAD). Approximately 6.8 mil-
ion people in U.S. suffer from CAD, and a steadily
ncreasing number of patients fall into the category in which
urrent revascularization techniques cannot be applied any
ore. Thus, novel treatments such as therapeutic angiogen-
sis might offer new hope also for approximately 100,000
atients in the U.S. only.
arly nonrandomized, uncontrolled trials. Small phase I
rials testing VEGF-A165 recombinant protein as an intra-
oronary infusion or naked VEGF-A165 plasmid as in-
ramyocardial injections via throracotomy “no-option” pa-
ients with CAD reported significant increases in exercise
apacity, improved contractile function, rest myocardial
erfusion, and angiographic collaterals (72–75). In a trial
sing naked VEGF-C (VEGF-2) plasmid DNA injected
ercutaneously into ischemic myocardium of 6 patients with
he NOGA catheter improved clinical status, alleviated
ngina, and reduced the area of ischemic myocardium (76).
ecently, 2-year results of an uncontrolled dose-escalation
tudy of 30 patients with Canadian Cardiovascular Society
CCS) class III or IV angina treated with intramyocardial
njection of naked VEGF-C (VEGF-2) plasmid DNA via
horacotomy were published (77). In the end of the follow-
p, 88.5 % of the patients were reported to have CCS class
or II angina pectoris and only 11% of the patients had
CS class III angina pectoris.
andomized, controlled trials. There are a few completed
hase II/III trials using VEGFs in patients with CAD
Table 2). In a phase II VIVA trial, a total of 178 patients
ere treated either with a low or high dose of recombinant
EGF-A165 protein (a 10-min intracoronary infusion fol-
owed by a 4-h intravenous infusion at day 3, 6, and 9) or
lacebo. No significant effect was found in the primary end
oint, which was treadmill exercise capacity at 4 months
44). However, the high dose of VEGF-A resulted in a
ignificant improvement on angina class as compared with
lacebo.
The study of Laitinen et al. (78) was the first randomized,
lacebo-controlled trial investigating the safety and feasibil-
ty of plasmid/liposome VEGF-A165 gene transfer in pa-
ients with stable CAD undergoing percutaneous coronary
ntervention (n  15). Gene transfer was found to be safe
nd well tolerated. The KAT (Kuopio Angioplasty phase II
rial) study aimed to investigate the efficacy of VEGF-A165
ene therapy on restenosis rate and myocardial perfusion as
iven during PCI (45). A total of 103 patients were
andomized to receive plasmid/liposome VEGF-A165,
dVEGF-A165, or placebo at the site of coronary angio-
lasty as a 10-min injection administered with a Dispatch
atheter (SCIMED Life Systems Inc., Maple Grove, Min-
esota) before stenting. There was no difference in the
estenosis rate (6%) between the study groups but myocar-
ial perfusion showed a significant improvement in the
dVEGF-A165 group at 6 months. pLosordo et al. (79) enrolled 19 no-option patients ran-
omized to percutaneous intramyocardial NOGA-delivery
f placebo or 3 different doses of naked VEGF-C plasmid
ith a crossover design. A significant reduction in CCS
ngina class in patients receiving VEGF-C plasmid after a
2-week follow-up was reported. In the Euroinject One
tudy, a total of 80 no-option CCS angina class III to IV
atients were assigned to intramyocardial injections of
aked plasmid VEGF-A165 or placebo with the NOGA
atheter (47). The injections were targeted to the area of
yocardium with a perfusion defect detected with SPECT.
fter a 3-month follow-up, no significant differences were
ound between the groups in CCS class or in the size of
erfusion defect at rest or during exercise. However, local
all motion as assessed by ventriculography or local linear
hortening mapping with NOGA were better in the plas-
id VEGF-A165–treated group than in the placebo group.
In the phase II REVASC (Randomized Evaluation of
EGF for Angiogenesis in Severe Coronary disease) trial,
o-option patients with CAD (n  67) with CCS class II
o IV angina were randomized to either continue best
tandard medical therapy or to receive AdVEGF121 (4 
010 pu) into the myocardium via thoracotomy (80). The
ime to 1-mm ST-segment depression during exercise test
as significantly improved at 26 weeks but not at 12 weeks
n patients who received AdVEGF121 compared with con-
rol patients. Secondary end points, CCS class, and total
xercise tolerance also were improved at 12 weeks. How-
ver, a significant contribution of a placebo effect in these
esults cannot be ruled out because of thoracotomy. The
hase II GENASIS trial was originally planned to enroll
04 no-option CAD patients with CCS III to IV angina for
ddressing the efficacy of percutaneous, intramyocardial
tiletto catheter (Boston Scientific Corporation, Natick,
assachusetts)-mediated naked VEGF-C (VEGF-2)
lasmid gene transfer on exercise tolerance time at 3
onths. However, this trial was recently prematurely
topped after 295 patients because of problems related to
he catheter and high likelihood of the lack of efficacy on
he primary end point. Currently, the phase II/III
ORTHERN trial (NOGA Angiogenesis Revasculariza-
ion Therapy: Evaluation by RadioNuclide Imaging)
planned n  120) is ongoing to test the efficacy of
ntramyocardial NOGA-mediated delivery of AdVEGF-
121 in no-option CAD patients. The NOVA (NOGA
elivery of VEGF for Angina) trial with very similar design
as recently stopped (Table 2).
afety of VEGF therapy. An important end point in all
EGF trials has been safety. Stimulation of angiogenesis
aises theoretical concerns, especially in relation to tumor
rowth, retinal neovascularization, hemorrhage from fragile
ew vessels, enhanced atherogenesis, hypotension, edema
nd inflammatory responses (1). So far, no evidence of
ncreased tumorigenesis, neovascularization in nontarget
rgans, vascular malformations, increased atherogenesis, or
laque destabilization has been observed in clinical trials
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March 13, 2007:1015–26 VEGFs in Cardiovascular Medicinesing VEGF-A protein or gene transfer (42–47). Excess
ascular structures also diminish in animal experiments after
xtinction of VEGF expression (55). High doses of
dVEGFs cause tissue edema and pericardial fluid accu-
ulation in animal experiments. Consistently, peripheral
dema was also found to be associated to the AdVEGF121
herapy in the RAVE trial (46). Recently, pericardial
ffusions were reported to occur in 1.37% of patients after
ercutaneous intramyocardial VEGF-C plasmid gene trans-
er in the GENASIS-trial, most likely related to Stiletto
atheter-mediated injections. Mild transient fever and de-
elopment of antiadenovirus antibodies have been reported
fter the intra-arterial administration of adenoviral vectors
43,45). In summary, according to current experience from
linical studies, treatment with VEGFs has been well
olerated, and no VEGF-related serious adverse effects have
een reported.
nsights From Clinical
rials and Future Perspectives
lacebo effect. All published uncontrolled gene or protein
EGF therapy trials have reported positive results. On the
ontrary, none of the randomized, controlled trials have
hown clinically relevant differences between the treated and
he placebo groups. Also, controlled trials using other
rowth factors or cytokines, such as recombinant FGF-2 or
ranulocyte macrophage colony-stimulating factor protein
r intracoronary AdFGF-4 have not been able to report
onvincing improvements in clinical outcomes (81–85).
hus, as a result of the strong placebo effect, randomized,
lacebo-controlled trials are necessary to assess the efficacy
f angiogenic therapies. In this respect, no exceptions can be
ade, even if most patients treated with this new technol-
gy have severe CAD or PAD, full medication and are
o-option patients for other revascularization treatments. In
roubleshooting of Clinical Therapeutic Angiogenesis Using VEGF
Table 3 Troubleshooting of Clinical Therapeutic Angiogenesis U
Problem
● Lack of clear clinical efficacy in randomized controlled
trials with VEGF recombinant protein or gene therapy
at 2 to 6 months in no-option PAD and CAD patients
● Short half-life of
● Low gene transfe
or intraarterial ge
● Too low adenovir
● Difficult or unres
● No definitive evidence of increased tissue perfusion
at 2 to 6 months in clinical VEGF gene therapy trials
despite large acute increases in animal models
● Too low gene tra
● Regression of im
after transient ad
● Angiogenesis-associated tissue edema ● VEGF increases v
● Increased perfus
proliferation in va
plasma protein e
AV  adeno-associated virus; i.m.  intramuscular/intramyocardial; other abbreviations as in Taddition to VEGF and other growth factors, cell-based oherapy for tissue ischemia has recently gained much atten-
ion (56,59,60). Currently, the 2 randomized controlled
linical trials using the whole mononuclear cell fraction
containing 0.1% endothelial progenitor cells) to treat
yocardial infarction with bone marrow-derived cells did
ot show a significant improvement in the left ventricular
unction (86,87). The reason(s) why randomized controlled
linical trials for therapeutic angiogenesis have not shown
ny therapeutic benefits is still somewhat unclear. Some
easons for the negative results and potential solutions are
hown in Table 3 and discussed herein.
atient selection. It may be possible that therapeutic
ngiogenesis just does not work as well in elderly patients as
n young animals. The main problem in ischemic tissue may
ot only be the availability of angiogenic growth factors (13)
ut also defects in the responsiveness to angiogenic stimuli
ue to severe atherosclerosis. However, because natural
ollateral vessel formation can rescue ischemic myocardium
nd lower limbs even in the elderly patients, the concept of
herapeutic angiogenesis seems valid but technical or phar-
acological shortcomings in the current treatment ap-
roaches may have caused the failures (49).
Standard medical therapy and current revascularization
ethods improve prognosis, relieve symptoms and can be
pplied to most patients with CAD and PAD. Thus,
o-option patients remain as the most likely target group for
EGF trials. A novel approach would be the combination
f conventional revascularization procedures with adjuvant
EGF gene therapy, which might represent the next step in
he development of clinically relevant proangiogenic treat-
ent. Recent findings on the role of blood flow as the
odulator of vascular growth support this kind of novel
oncept in which peripheral angiogenesis could improve the
run-off” of grafts and possibly lead to better outcomes
55,88). Importantly, in this setting also other than no-
VEGF
ason Potential Solutions
ecombinant protein
iency with naked plasmid
nsfer route
with i.m. route
e patient population
● Intramuscular gene transfer route
● Optimized viral dose
● Wider spread of angiogenesis using sufficient
volume and number of injections
● Use of VEGF gene transfer as adjuvant
therapy in combination with conventional
revascularization procedures
fficiency
e vessels within 2 weeks
al gene transfer
● Perfusion measurement 5 to 6 days after
AdVEGF gene transfer to show “proof-of-
principle” of increased perfusion in humans
● Use of AAV, lentiviruses, gutless adenoviruses,
or other vectors that produce long-term VEGF
expression
r permeability directly
pillary pressure, and cell
wall cause additional
sation
● Optimal viral dose
● Vessel maturation via long-term VEGF
expression via AAV
● Regulation of transgene expression
● Growth factor combinationssing
Re
VEGF r
r effic
ne tra
al dose
ponsiv
nsfer e
matur
enovir
ascula
ion, ca
scular
xtravaption patients would become eligible for VEGF trials
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VEGFs in Cardiovascular Medicine March 13, 2007:1015–26hich might increase the likelihood of more positive clinical
utcomes.
ene-delivery methods. The most likely explanation for
he negative clinical results is that growth factor concentra-
ion in human tissues has not reached sufficient levels and/or
as not persisted long enough for triggering relevant vascu-
ar growth. This, in turn, can result from several factors,
uch as the short half-life of recombinant growth factors,
nsufficient dose of adenovirus, too short a time for gene
xpression or compromised delivery route such as intra-
rterial injection. Intra-arterially injected material (gene
ransfer vector or cells) is less effective (15), unlikely reaches
reas with severely impaired perfusion i.e. areas with the
reatest need of therapeutic effect but instead results in a
onsiderable systemic spread of the injected agent. Pericar-
ial delivery is also unlikely to result in an efficient
ransmyocardial transduction. Intramuscular and intramyo-
ardial injections are currently most effective and the latter
an be performed percutaneously without the need of
horacotomy by using the intracardiac catheter systems.
In the Euroinject One and GENASIS trials, intramyo-
ardial injections of naked VEGF-A165 or -C plasmid have
ikely yielded too-low transfection efficiency (47). This
esult is also in line with our experimental results in pigs, in
hich the intramyocardial NOGA catheter-mediated injec-
ion of naked VEGF-A or -DNC plasmid did not induce
ignificant protein production or any vascular effects (52). In
he RAVE trial, the adenoviral VEGF-A121 dose was
pproximately 2 logs less per kilogram than what has been
sed in the recent preclinical experiments showing very high
ngiogenic efficacy in addition to approximately 2 logs lower
iological efficacy of VEGF121 than that of VEGF165
2,22,46,55). Despite large initial perfusion increases at
round a week after AdVEGF165 injections, it may be that
ectors such as adeno-associated virus or lentivirus capable
f long-term gene expression are needed to achieve clinically
elevant vascular growth.
nd points. Before gene therapy can become an estab-
ished method for revascularization, it must demonstrate its
apability to relieve symptoms and reduce adverse end
oints or mortality/amputations in patients with CAD and
AD. Because an improvement in mortality is difficult to
chieve, surrogate end points such as exercise capacity and
issue perfusion often are used. Exercise capacity or walking
ime/distance are very relevant clinical end points, but have
he disadvantage that in the end-stage CAD and PAD
atients they are very subjective measures and show great
ntraindividual variation. Another end point used in previ-
us trials, the size of perfusion defect at rest or during
xercise assessed with single-photon emission computed
omography (SPECT), also has its limitations. Instead, the
ybrid SPECT or PET and computed tomography
SPECT/CT or PET/CT) and novel magnetic resonance
maging techniques might be used for the assessment of
yocardial perfusion and function. Importantly, most of the
mall molecular contrast media such as iodine X-ray con-rast agents and gadolinium extravasate from angiogenic,
yperpermeable vessels (22,55). On the contrary, novel
ontrast-enhanced ultrasound techniques using large 3-m
icrobubbles provide reliable measurement of tissue perfu-
ion during angiogenesis (55).
ollow-up time. The follow-up time needs to be long
nough to reveal long-term benefits and potential side-
ffects of the VEGF therapy. On the other hand, athero-
clerosis is a progressive disease and to avoid the effects of
his confounding factor it can be recommended that the
rimary end point should be evaluated at 3 to 6 months after
he VEGF therapy. However, a short time point of 5 to 6
ays after adenoviral gene transfer also should be evaluated
o document the peak increase in myocardial or skeletal
uscle perfusion as well as maximal tissue edema according
o the transient gene expression kinetics of adenovirus
51,55). To assess potential long-term effects of the therapy,
ollow-up for 3 years is recommended.
onclusions
he promising preclinical results obtained in animal exper-
ments with VEGF therapy have not yet been translated
nto clinical success. However, VEGFs have tremendous
otential as vascular therapeutics and, therefore, the opti-
ization of the indications of the therapy and the ongoing
evelopments in gene delivery techniques are expected to
ead to the generation of novel treatment for ischemic
ardiovascular disease.
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